a Collaborative Antwerp Psychiatric Research Institute (CAPRI), Faculty of Medical and Health Sciences , University of Antwerp , Antwerpen , Belgium.
b University Department , Psychiatric Hospital Duffel , Duffel , Belgium.
Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):999-1005. doi: 10.1080/17425255.2018.1515911. Epub 2018 Sep 7.
Bipolar disorder is a severe, chronic psychiatric disorder with a need for long-term treatment. Patient nonadherence is frequent and poses a major problem in maintenance therapy. Aripiprazole once-monthly long-acting injectable (AOM LAI) is a recently US Food and Drug Administration-approved treatment option for maintenance therapy that could be of great value. Areas covered: This paper reviews the pharmacokinetic, efficacy and safety data for AOM LAI in bipolar disorder. Expert opinion: AOM LAI is a safe and efficacious treatment option in the maintenance therapy of bipolar I disorder. However, further research is still needed to determine the position of AOM LAI relative to other available treatment options.
双相障碍是一种严重的、慢性精神疾病，需要长期治疗。患者不依从治疗的情况很常见，是维持治疗中的一个主要问题。阿立哌唑一月注射一次长效针剂（AOM LAI）是最近获得美国食品和药物管理局批准的维持治疗选择，可能具有重要价值。 涵盖领域：本文综述了阿立哌唑一月注射一次长效针剂在双相障碍中的药代动力学、疗效和安全性数据。 专家意见：AOM LAI 是双相 I 障碍维持治疗的一种安全有效的治疗选择。然而，仍需要进一步研究来确定 AOM LAI 相对于其他可用治疗选择的地位。
